# A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

> **NCT05996848** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 300 (actual)

## Conditions studied

- Obesity or Overweight

## Interventions

- **DRUG:** Cagrilintide
- **DRUG:** Semaglutide
- **DRUG:** Placebo Semaglutide
- **DRUG:** Placebo Cagrilintide

## Key facts

- **NCT ID:** NCT05996848
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-15
- **Primary completion:** 2025-01-06
- **Final completion:** 2025-02-22
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05996848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05996848, "A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05996848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*